Replies to post #226171 on Biotech Values

[DewDiligence]

STSA—(-75%)—fails acute-migraine phase-3:

https://finance.yahoo.com/news/satsuma-pharmaceuticals-announces-topline-results-120000911.html

Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration.

The stock is now down 60% from its 2019 IPO (#msg-151112084).